1030612-90-8 | MK8245

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$88.00	$62.00
5mg	98%	in stock	$205.00	$144.00
10mg	98%	in stock	$306.00	$214.00
25mg	98%	in stock	$520.00	$364.00
50mg	98%	in stock	$675.00	$473.00
100mg	98%	in stock	$872.00	$610.00
250mg	98%	in stock	$1,449.00	$1,014.00
1g	98%	in stock	$3,600.00	$2,520.00

Description

• Catalog Number: AE11289
• Chemical Name: MK8245
• CAS Number: 1030612-90-8
• Molecular Formula: C17H16BrFN6O4
• Molecular Weight: 467.2491
• MDL Number: MFCD20039622
• SMILES: OC(=O)Cn1nnc(n1)c1onc(c1)N1CCC(CC1)Oc1cc(F)ccc1Br

Computed Properties

• Complexity: 572
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 3.4

Upstream Synthesis Route

Mk-8245, a powerful inhibitor used in chemical synthesis, is an invaluable tool in the realm of organic chemistry. This compound plays a pivotal role in the development of novel pharmaceuticals by effectively targeting key enzymes involved in metabolic pathways. Through its precise mechanism of action, Mk-8245 facilitates the synthesis of intricate molecular structures with enhanced efficiency and precision. Chemists harness the unique properties of Mk-8245 to manipulate complex reactions, paving the way for the creation of innovative compounds with diverse applications in drug discovery and development. By incorporating Mk-8245 into synthetic processes, researchers are able to streamline production workflows and achieve higher yields of target molecules, ultimately advancing the frontiers of chemical synthesis.

Literature

• Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.

  Bioorganic & medicinal chemistry letters 20120101

• Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors.

  Journal of lipid research 20110801

• Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

  Journal of medicinal chemistry 20110728